A simple blood test can now determine how well chemotherapy is working in Hodgkin lymphoma patients, a study has revealed.
Researchers found levels of a certain protein – CD163 – become elevated in Hodgkin lymphoma patients' serum and drop as the tumour shrinks during chemotherapy.
The findings could lead to personalised treatments for patients suffering from the disease.
There are no comments on this article yet.
To have your say and join The Conversation please sign in if you have an account already, or sign up.